Cargando…

Bilateral Central Serous Chorioretinopathy After Treatment of COVID-19 Infection

We report a rare case of bilateral central serous chorioretinopathy (CSCR) after COVID-19 management with steroids. The patient was a 49-year-old female who presented with bilateral blurred vision three months after the COVID-19 infection. She had been treated with intravenous Remdesivir and Dexamet...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharifi, Ali, Daneshtalab, Arash, Zand, Amin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038508/
https://www.ncbi.nlm.nih.gov/pubmed/35494916
http://dx.doi.org/10.7759/cureus.23446
_version_ 1784693938304581632
author Sharifi, Ali
Daneshtalab, Arash
Zand, Amin
author_facet Sharifi, Ali
Daneshtalab, Arash
Zand, Amin
author_sort Sharifi, Ali
collection PubMed
description We report a rare case of bilateral central serous chorioretinopathy (CSCR) after COVID-19 management with steroids. The patient was a 49-year-old female who presented with bilateral blurred vision three months after the COVID-19 infection. She had been treated with intravenous Remdesivir and Dexamethasone. After her recovery from the disease, she developed gradual visual impairment in both her eyes. Upon examinations and optical coherence tomography, bilateral CSCR was revealed. She was treated with eplerenone (25 mg/day) and propranolol (20 mg/day), and the symptoms were improved after two months. Post-COVID-19 associated CSCR can occur due to steroids administration. Therefore, patients and physicians should be aware of these possible complications and seek an ophthalmology consultation as early as possible.
format Online
Article
Text
id pubmed-9038508
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-90385082022-04-27 Bilateral Central Serous Chorioretinopathy After Treatment of COVID-19 Infection Sharifi, Ali Daneshtalab, Arash Zand, Amin Cureus Ophthalmology We report a rare case of bilateral central serous chorioretinopathy (CSCR) after COVID-19 management with steroids. The patient was a 49-year-old female who presented with bilateral blurred vision three months after the COVID-19 infection. She had been treated with intravenous Remdesivir and Dexamethasone. After her recovery from the disease, she developed gradual visual impairment in both her eyes. Upon examinations and optical coherence tomography, bilateral CSCR was revealed. She was treated with eplerenone (25 mg/day) and propranolol (20 mg/day), and the symptoms were improved after two months. Post-COVID-19 associated CSCR can occur due to steroids administration. Therefore, patients and physicians should be aware of these possible complications and seek an ophthalmology consultation as early as possible. Cureus 2022-03-24 /pmc/articles/PMC9038508/ /pubmed/35494916 http://dx.doi.org/10.7759/cureus.23446 Text en Copyright © 2022, Sharifi et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Ophthalmology
Sharifi, Ali
Daneshtalab, Arash
Zand, Amin
Bilateral Central Serous Chorioretinopathy After Treatment of COVID-19 Infection
title Bilateral Central Serous Chorioretinopathy After Treatment of COVID-19 Infection
title_full Bilateral Central Serous Chorioretinopathy After Treatment of COVID-19 Infection
title_fullStr Bilateral Central Serous Chorioretinopathy After Treatment of COVID-19 Infection
title_full_unstemmed Bilateral Central Serous Chorioretinopathy After Treatment of COVID-19 Infection
title_short Bilateral Central Serous Chorioretinopathy After Treatment of COVID-19 Infection
title_sort bilateral central serous chorioretinopathy after treatment of covid-19 infection
topic Ophthalmology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038508/
https://www.ncbi.nlm.nih.gov/pubmed/35494916
http://dx.doi.org/10.7759/cureus.23446
work_keys_str_mv AT sharifiali bilateralcentralserouschorioretinopathyaftertreatmentofcovid19infection
AT daneshtalabarash bilateralcentralserouschorioretinopathyaftertreatmentofcovid19infection
AT zandamin bilateralcentralserouschorioretinopathyaftertreatmentofcovid19infection